Showing results (281-290 of 298) with videos related to

Sort By:
Pageof 30
Clinical Lung Cancer|January 3, 2026
Multicenter Real-World Data on First-Line Chemoimmunotherapy in Patients With Advanced Non-Small Cell Lung Cancer and Performance Status 2: WJOG18424LShunichi Kataoka, Takehito Shukuya, Hiroshi Ohtsu, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2024
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND)Daichi Fujimoto, Hidetoshi Hayashi, Kenta Murotani, et al.
Cancer Treatment and Research Communications|July 4, 2024
Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancerKanako Sakaeda, Koji Kurose, Yuki Matsumura, et al.
Science (New York, N.Y.)|January 28, 2016
Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobinTakeshi Masuda, Xin Wang, Manami Maeda, et al.
The Journal of Antibiotics|August 16, 2019
Muraminomicins, new lipo-nucleoside antibiotics from Streptosporangium sp. SANK 60501-structure elucidations of muraminomicins and supply of the core component for derivatizationYoko Fujita, Yoshiko Kagoshima, Takeshi Masuda, et al.
Advances in Clinical Chemistry|January 15, 2023
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markersKoji Kurose, Kanako Sakaeda, Minoru Fukuda, et al.
Respirology (Carlton, Vic.)|June 4, 2026
Baseline Neutrophil-To-Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non-Small Cell Lung Cancer: A Two-Cohort Study With Retrospective Discovery and Prospective ValidationTetsu Hirakawa, Kakuhiro Yamaguchi, Shun Takao, et al.
The Journal of Clinical Investigation|October 3, 2023
A splice-switching oligonucleotide treatment ameliorates glycogen storage disease type 1a in mice with G6PC c.648G>TKentaro Ito, Go Tajima, Chikako Kamisato, et al.
British Journal of Cancer|March 23, 2024
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancerKoji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, et al.
ESMO Open|July 22, 2020
Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR)Kyoichi Okishio, Ryo Morita, Junichi Shimizu, et al.
Pageof 30